Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding J.P.H. et al.
Editor's note
The trial that turned semaglutide into a household word. 14.9% mean body-weight reduction at 68 weeks vs. 2.4% on placebo across 1,961 adults — the result that opened the floodgates for the entire GLP-1 wave.